Table 1.
Demographic and clinical characteristics of the discovery cohort.
| Obese Asthmatic (n=21) |
Normal-weight Asthmatic (n=21) |
P value | |
|---|---|---|---|
| Age (years) | 9.1±1.5 | 8.9± 0.6 | 0.76 |
| Males (n(%)) | 8 (38.1) | 10 (47.6) | 0.75 |
| Hispanic (n(%)) | 15 (71.4) | 12 (57.4) | 0.52 |
| BMI-z score | 1.9 ± 0.4 | 0.06 ± 0.8 | <0.001 |
| Atopic sensitization# | 17 (81) | 20 (95.2) | 0.01 |
| Insulin | 11.9 ± 7.5 | 8.5 ± 4.7 | 0.08 |
| FVC* | 102 ± 11.1 | 89.7 ± 12.3 | 0.002 |
| FEV1* | 96.2 ± 16.7 | 87.1 ± 16.4 | 0.08 |
| FEV1/FVC | 81.7 ± 7.5 | 84.5 ± 8.4 | 0.27 |
| TLC* | 92.6 ± 13.5 | 92 ± 11 | 0.88 |
| RV* | 86.6 ± 36.2 | 120.4 ± 33.7 | 0.004 |
| RV/TLC* | 22 ± 6.2 | 31.8 ± 6 | <0.001 |
| ERV* | 77.2 ± 17.7 | 81.1 ± 29.7 | 0.62 |
| FRC* | 85.3 ± 19.4 | 105.8 ± 23.4 | 0.005 |
| Medication use | |||
| Inhaled steroids | 11 (52.3) | 9 (42.9) | 0.75 |
| Montelukast | 13 (61.9) | 9 (42.9) | 0.35 |
| Inhaled steroid/ long acting beta agonist combination therapy | 3 (14.3) | 4 (19) | 1 |
All continuous variables are reported as mean±SD.
Categorical variables (gender (males), ethnicity (Hispanic)), atopic sensitization, and medication use are reported as group-specific numerical frequency and percentages.
*
Pulmonary function variables are reported as percent predicted values, other than FEV1/FVC and RV/TLC ratio, which are reported as percentages.
#
Atopic sensitization was defined as skin prick test reactivity to one or more allergens.47